Discovery of Kv7 (KCNQ) Channel Openers for CNS Hyperexcitability Disorders

Mechanism of action, sub-type selectivity, and functional studies using iPSC-derived neurons.


View Webinar


Potassium channels are important drug development targets for a wide variety of human health conditions including those arising from neuronal hyperexcitability. Icagen scientists, in collaboration with pharma partners, have advanced multiple potassium channel modulators from early discovery phase through to clinical trials. This webinar will focus on Icagen's expertise and capabilities in this channel family with special emphasis on the Kv7 (KCNQ) class of voltage-dependent channels. Kv7 genetic variants are linked to various forms of epilepsy as these channels are involved in membrane potential stabilization, action potential repolarization and modulation of neuronal bursting patterns. Data will be presented on the mechanism of action of Kv7 modulators, Icagen's discovery of sub-type selective openers and the use of iPSC-derived neurons for translational studies to accelerate identification of clinical candidates.

Webinar attendees will learn about:

  • The therapeutic potential and the diverse mechanism of action of Kv7 channel openers
  • Molecular interactions important for achieving sub-type selectivity
  • Use of iPSC-derived neurons to investigate effects on excitability and to support translation
  • Icagen's experience and expertise in potassium channel drug discovery

Discussions lead by:

Doug Krafte, Ph.D.
CSO, Icagen, Inc.

Aaron Gerlach, Ph.D.
Senior Principal Scientist, Icagen